EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

Shai Shimony iD, Maximilian Stahl iD, Richard M Stone iD

American Journal of Hematology · 2023-03 · 98 (3) · 502-526

DOI: 10.1002/ajh.26822 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 13.01.2023. Verfasst von Shai Shimony und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 451-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding. An improved understanding of pathophysiology, improvements in measurement technology and at least 10 recently approved therapies have led to revamping the diagnostic, prognostic, and therapeutic landscape of AML. Diagnosis One updated and one new classification system were published in 2022, both emphasizing the integration of molecular analysis into daily practice. Differences between the International Consensus Classification and major revisions from the previous 2016 WHO system provide both challenges and opportunities for care and clinical research. Risk assessment and monitoring The European Leukemia Net 2022 risk classification integrates knowledge from novel molecular findings and recent trial results, as well as emphasizing dynamic risk based on serial measurable residual disease assessment. However, how to leverage our burgeoning ability to measure a small number of potentially malignant myeloid cells into therapeutic decision making is controversial. Risk adapted therapy The diagnostic and therapeutic complexity plus the availability of newly approved agents requires a nuanced therapeutic algorithm which should integrate patient goals of care, comorbidities, and disease characteristics including the specific mutational profile of the patient's AML. The framework we suggest only represents the beginning of the discussion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansBone MarrowMutationPrognosisRisk Assessment

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

ORCID-Profile: Shai Shimony, Maximilian Stahl, Richard M Stone

Zitieren

APA

Shimony, S., Stahl, M., & Stone, R. M. (2023). Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98(3), 502-526. https://doi.org/10.1002/ajh.26822

Vancouver

Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2023;98(3):502-526. doi:10.1002/ajh.26822

BibTeX
@article{Shimony2023,
  author = {Shimony, Shai and Stahl, Maximilian and Stone, Richard M},
  title = {Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {3},
  pages = {502--526},
  doi = {10.1002/ajh.26822}
}
Kostenlos starten →